Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

NCT00162851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B-CLL

Interventions

DRUG: alemtuzumab

Sponsor

Karolinska University Hospital

Collaborators

[object Object]